Pharmaceutical Executive Europe - January 2008 - (Page 7)

Finding value in pharma needn't be this complex With EvaluatePharma® Alpha it’s not. Specifically designed to identify the events that shape the constantly evolving pharma and biotech markets – and quantify their impact – EvaluatePharma® Alpha is the new premium service from EvaluatePharma®. The three key tools that comprise EvaluatePharma® Alpha work in synergy to give you the capability to assess the potential value of development projects, licensing deals and acquisition targets that are crucial to your commercial success. Interactive NPV Analyzer: consensus NPV data for 2500 products, plus interactive interface for "what if" modelling Calendar of Events: tracks key industry and market events that will shape the future value of products and companies EP Vantage: commentary and proprietary analysis of critical news and events with key opinion leader insight For a FREE sample NPV report, simply email alpha@evaluatepharma.com, entering: “NPV sample EPE” as the subject. www.evaluatepharma.com/alpha To arrange a demonstration and FREE trial, please contact: Will Hau – Sales Director Europe – e: willh@evaluatepharma.com – t: +44 (0)7984 435 010 http://www.evaluatepharma.com/alpha http://www.evaluatepharma.com/alpha

Table of Contents Feed for the Digital Edition of Pharmaceutical Executive Europe - January 2008

Pharmaceutical Executive Europe - January 2008 Contents From the Editor News and Analysis Calendar Corporate Strategy: Walking the Line Executive Profile: The Pharmacist’s Friend Q&A: An End to Drug Counterfeiting Healthcare Cost Assessment: Ready to Make NICE? Pricing and Reimbursement: Through the Reimbursement Barriers Generics: India Inc. The Mix: New Models of Excellence Last Word: Mid-size Matters

Pharmaceutical Executive Europe - January 2008

Pharmaceutical Executive Europe - January 2008 - Pharmaceutical Executive Europe - January 2008 (Page 1) Pharmaceutical Executive Europe - January 2008 - Pharmaceutical Executive Europe - January 2008 (Page 2) Pharmaceutical Executive Europe - January 2008 - Contents (Page 3) Pharmaceutical Executive Europe - January 2008 - From the Editor (Page 4) Pharmaceutical Executive Europe - January 2008 - From the Editor (Page 5) Pharmaceutical Executive Europe - January 2008 - News and Analysis (Page 6) Pharmaceutical Executive Europe - January 2008 - News and Analysis (Page 7) Pharmaceutical Executive Europe - January 2008 - News and Analysis (Page 8) Pharmaceutical Executive Europe - January 2008 - News and Analysis (Page 9) Pharmaceutical Executive Europe - January 2008 - News and Analysis (Page 10) Pharmaceutical Executive Europe - January 2008 - News and Analysis (Page 11) Pharmaceutical Executive Europe - January 2008 - Calendar (Page 12) Pharmaceutical Executive Europe - January 2008 - Calendar (Page 13) Pharmaceutical Executive Europe - January 2008 - Corporate Strategy: Walking the Line (Page 14) Pharmaceutical Executive Europe - January 2008 - Corporate Strategy: Walking the Line (Page 15) Pharmaceutical Executive Europe - January 2008 - Corporate Strategy: Walking the Line (Page 16) Pharmaceutical Executive Europe - January 2008 - Corporate Strategy: Walking the Line (Page 17) Pharmaceutical Executive Europe - January 2008 - Executive Profile: The Pharmacist’s Friend (Page 18) Pharmaceutical Executive Europe - January 2008 - Executive Profile: The Pharmacist’s Friend (Page 19) Pharmaceutical Executive Europe - January 2008 - Q&A: An End to Drug Counterfeiting (Page 20) Pharmaceutical Executive Europe - January 2008 - Q&A: An End to Drug Counterfeiting (Page 21) Pharmaceutical Executive Europe - January 2008 - Healthcare Cost Assessment: Ready to Make NICE? (Page 22) Pharmaceutical Executive Europe - January 2008 - Healthcare Cost Assessment: Ready to Make NICE? (Page 23) Pharmaceutical Executive Europe - January 2008 - Healthcare Cost Assessment: Ready to Make NICE? (Page 24) Pharmaceutical Executive Europe - January 2008 - Pricing and Reimbursement: Through the Reimbursement Barriers (Page 25) Pharmaceutical Executive Europe - January 2008 - Pricing and Reimbursement: Through the Reimbursement Barriers (Page 26) Pharmaceutical Executive Europe - January 2008 - Pricing and Reimbursement: Through the Reimbursement Barriers (Page 27) Pharmaceutical Executive Europe - January 2008 - Generics: India Inc. (Page 28) Pharmaceutical Executive Europe - January 2008 - Generics: India Inc. (Page 29) Pharmaceutical Executive Europe - January 2008 - Generics: India Inc. (Page 30) Pharmaceutical Executive Europe - January 2008 - The Mix: New Models of Excellence (Page 31) Pharmaceutical Executive Europe - January 2008 - The Mix: New Models of Excellence (Page 32) Pharmaceutical Executive Europe - January 2008 - The Mix: New Models of Excellence (Page 33) Pharmaceutical Executive Europe - January 2008 - The Mix: New Models of Excellence (Page 34) Pharmaceutical Executive Europe - January 2008 - Last Word: Mid-size Matters (Page 35) http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091208http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091124http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091110http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091027http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091013http://digital.findpharma.com/nxtbooks/advanstaruk/PEE_DIGEST_20090930http://digital.findpharma.com/nxtbooks/advanstaruk/PEE_digest_20090916http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090902http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090825http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090819http://digital.findpharma.com//nxtbooks/advanstaruk/pee_digest_20090812http://digital.findpharma.com//nxtbooks/advanstaruk/pee_digest_20090805http://digital.findpharma.com//nxtbooks/advanstaruk/pee_digest_20090729http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090721http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090715http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090708http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090701http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090624http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090617http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090610http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090602http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090526http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090519http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090512http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090505http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_southafricahttp://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090429http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090422http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090415http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090408http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090401_v2http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090401http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090325http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090318http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090311http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090304http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090224http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090218http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090211http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090203http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090128http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090121http://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090114http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope1008http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-ims1008http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0908http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0808http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0708http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0608http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-imssales0508http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0508http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0408http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0308http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0208http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-imssales0208http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0108http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-ims1207http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope1107http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope1007http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-imsoncology0907http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0407http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0307http://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope1206http://www.nxtbookMEDIA.com

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.